Schizophrenia

Published on 02/03/2015 by admin

Filed under Basic Science

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1321 times

30 Schizophrenia

The concept of schizophrenia can be difficult to understand. People who do not suffer from schizophrenia can have little idea of what the experience of hallucinations and delusions is like. The presentation of schizophrenia can be extremely varied, with a great range of possible symptoms. There are also many misconceptions about the condition of schizophrenia that have led to prejudice against sufferers of the illness. People with schizophrenia are commonly thought to have low intelligence and to be dangerous. In fact, only a minority shows violent behaviour, with social withdrawal being a more common picture. Up to 10% of people with schizophrenia commit suicide.

Symptoms and diagnosis

Acute psychotic illness

To establish a definite diagnosis of schizophrenia it is important to follow the diagnostic criteria in either DSM IV or ICD 10, but symptoms which commonly occur in the acute phase of a psychotic illness include the following:

These symptoms are commonly called positive symptoms.

Causes of schizophrenia

Although the cause of schizophrenia remains unknown, there are many theories and models.

Drug treatment

Mode of action of antipsychotic drugs

Although the cause of schizophrenia is the subject of controversy, an understanding of the mode of action of antipsychotic drugs has led to the dopamine theory of schizophrenia. This theory postulates that the symptoms experienced in schizophrenia are caused by an alteration to the level of dopamine activity in the brain. It is based on knowledge that dopamine receptor antagonists are often effective antipsychotics while drugs which increase dopamine activity, such as amfetamine, can either induce psychosis or exacerbate a schizophrenic illness.

At least six dopamine receptors exist in the brain, with much activity being focused on the D2 receptor as being responsible for antipsychotic drug action. However, drugs such as pimozide, that claim to have a more specific effect on D2 receptors, do not appear superior in antipsychotic effect when compared to other agents.

Research into the mode of action of clozapine has caused a change of attention to the mesolimbic system in the brain and to different receptors. Clozapine does not chronically alter striatal D2 receptors but does appear to affect striatal D1 receptors. It also appears to have more effect on the limbic system and on serotonin (5HT2) receptors, which may explain its reduced risk of extrapyramidal symptoms. The term ‘atypical’ is used to categorise those antipsychotic drugs that, like clozapine, rarely produce extrapyramidal side effects (EPSEs).

Although the reason for the superiority of clozapine in schizophrenia treatment remains an enigma, a variety of theories have led to the development of a new family of antipsychotic drugs. Some mimic the impact of clozapine on a wide range of dopamine and serotonin receptors, for example, olanzapine, others mimic the impact on particular receptors, for example, 5HT2/D2 receptor antagonists such as risperidone, others focus on limited occupancy of D2 receptors, for example, quetiapine, while others focus on alternative theories such as partial agonism (aripiprazole).

Rationale for use of drugs

Although a variety of social and psychological therapies are helpful in the treatment of schizophrenia, drugs form the essential cornerstone. The aim of all therapies is to minimise the level of handicap and achieve the best level of mental functioning. Drugs do not cure schizophrenia and are only partially effective at eradicating some symptoms such as delusions and negative symptoms. At the same time, benefits have to be balanced against side effects and whether the need to suppress particular symptoms is important. For example, if the person has a delusion that he or she is responsible for famine in Africa, but this does not in any way influence that person’s behaviour or mood, a common view would be that there would be little point in increasing antipsychotic drug therapy. However, others would argue that this ‘untreated’ delusion would make the person stand out or be subject to social stigma and the delusion should be more aggressively treated. If, on the other hand, this delusion led to great distress, or violent or dangerous behaviour, then an increase in antipsychotic drugs would usually be indicated.

It is now accepted that antipsychotic drugs can control or modify symptoms such as hallucinations and delusions that are evident in the acute episode of illness. Except for clozapine and the other atypicals, there is little evidence for antipsychotic drugs being of value in the treatment of the negative symptoms, although the matter remains controversial (Chakos et al., 2001). Antipsychotic drugs increase the length of time between breakdowns and shorten the length of the acute episode in most patients.

Drug selection and dose

Over the years there have been many changes to the range of antipsychotic drugs available. Despite the availability of newer agents many of the issues relevant to drug selection and dose have remained similar for the last 50 years and include:

Side effects

For older, typical antipsychotic drugs, side effects such as hypotension, extrapyramidal symptoms and anticholinergic effects are key factors in the choice of drug. In contrast, with the newer atypical drugs, side effects such as diabetes, sexual dysfunction and weight gain affect adherence in many patients. Sedation remains a factor for all antipsychotic drugs.

The key side effects of concern are those categorised as EPSEs. Those that caused these side effects were called typical antipsychotic drugs and those that did not were called atypical. This classification system, however, has always remained subject to criticism as some atypicals will cause EPSEs when used at higher doses and the side effects of the different atypicals can vary considerably. EPSEs include:

Akathisia or motor restlessness. This causes patients to pace up and down, constantly shift their leg position or tap their feet.

Dystonia is the result of sustained muscle contraction. It can present as grimacing and facial distortion, neck twisting and laboured breathing. Occasionally the patient may have an oculogyric crisis in which, after a few moments of fixed staring, the eyeballs move upwards and then sideways, remaining in that position. In addition to these eye movements, the mouth is usually wide open, the tongue protruding and the head tilting backwards.

Parkinson-like side effects usually present as tremor, rigidity and poverty of facial expression. Drooling and excessive salivation are also common. A shuffling gait may be seen and the patient may show signs of fatigue when performing repetitive motor activities.

Another movement disorder more commonly associated with typical antipsychotics is tardive dyskinesia. Tardive dyskinesia normally affects the tongue, facial and neck muscles but can also affect the extremities. Individuals with tardive dyskinesia often have abnormalities of posture and movement of the fingers in addition to the oral-lingual-masticatory movements.

Epidemiological studies support the association between the prescribing of typical antipsychotic drugs and the development of tardive dyskinesia. Other factors which also appear to be associated include the duration of exposure to antipsychotic drugs, the co-prescribing of anticholinergic drugs, the co-prescribing of lithium, advanced age, prior experience of acute extrapyramidal symptoms and brain damage. Many other factors have been postulated to be associated with tardive dyskinesia such as depot formulations of antipsychotic drugs, dosage of antipsychotic drug and antipsychotic drugs with high anticholinergic activity, but such associations remain unproven.

Although the mechanism by which tardive dyskinesia arises is unclear, the leading hypothesis is that after prolonged blockade of dopamine receptors, there is a paradoxical increase in the functional activity of dopamine in the basal ganglia occurs. This increased functional state is thought to come about through a phenomenon of disuse supersensitivity of dopamine receptors. The primary clinical evidence to support this theory arises because tardive dyskinesia is late in onset following prolonged exposure to antipsychotic drugs and has a tendency to worsen upon abrupt discontinuation of the antipsychotic drug.

Attempts to treat tardive dyskinesia have been many and varied. Treatments include use of dopamine-depleting agents such as reserpine and tetrabenazine, dopamine-blocking agents such as antipsychotic drugs, interference with catecholamine synthesis by drugs such as methyldopa, cholinergic agents such as choline and lecithin, use of GABA mimetic agents such as sodium valproate and baclofen, and the provision of drug holidays. Rarely are these strategies successful. Most successful strategies currently involve a gradual withdrawal of the typical antipsychotic drug and replacement with an atypical antipsychotic drug.

Concerns about the EPSEs and toxicity of typical antipsychotic drugs led to calls over the past 10 years for the ‘atypicals’ to be prescribed more widely. This approach was supported in national guidance which advocated that atypical antipsychotic drugs should be used for the treatment of a first illness. However, increasing concern about the side effects of the atypical antipsychotic drugs, which includes weight gain, diabetes and sexual dysfunction, has led many clinicians to question the benefits of the newer and more expensive atypical antipsychotics. In more recent guidance (National Institute for Health and Clinical Excellence, 2009), it has been advocated that:

Information on the advantages and disadvantages of the various antipsychotic drugs can be found in Table 30.1.

Table 30.1 Neuroleptics/antipsychotics and their commonly associated attributes and problems

Drug group Drug Comment
Butyrophenones Haloperidol Regarded as the gold standard reference antipsychotic
    Extrapyramidal side effects of parkinsonian rigidity, dystonia, akathisia
    Tardive dyskinesia with long-term use
    Drug most associated with neuroleptic malignant syndrome
    Sedation common
    Hormonal effects common
    Wide range of formulations including long-acting injection
  Benperidol As haloperidol
    Claimed to reduce sexual drive, although little evidence to support the claim
Phenothiazines    
Piperidine Pericyazine Marked anticholinergic side effects of dry mouth, blurred vision and constipation
    Postural hypotension and falls in the elderly
    Lower incidence of extrapyramidal side effects
  Pipotiazine As pericyazine but only available as depot formulation
Aliphatic Chlorpromazine As haloperidol but in addition postural hypotension, low body temperature, rashes and photosensitivity
    Increased sedative effects
  Promazine As chlorpromazine but low potency
    Considered by some to have weak antipsychotic effect
  Levomepromazine Very sedative and postural hypotension common
  (methotrimeprazine) Mostly used in terminal illness
Piperazine Trifluoperazine As chlorpromazine but greater incidence of extrapyramidal side effects and lower incidence of anticholinergic effects
    Tardive dyskinesia with long-term use
    Some antiemetic properties
  Fluphenazine As trifluoperazine but also available as depot formulation
  Perphenazine As trifluoperazine
Thioxanthines Flupentixol Similar to fluphenazine but also available as depot formulation
  Zuclopenthixol Similar to chlorpromazine but also available as depot formulation
Diphenylbutylpiperidines Pimozide As haloperidol but concerns about cardiac effects at high dose limits use
Benzamides Sulpiride Lower incidence of extrapyramidal effects
    Few anticholinergic effects
    Useful adjunct to clozapine in refractory illness
  Amisulpride As sulpiride
Dibenoxazepine tricyclics Clozapine Drug of choice for treatment-resistant schizophrenia
    Low incidence of extrapyramidal side effects or tardive dyskinesia
    Neutropenia in 1–2% of cases
    Enhanced efficacy against both positive and negative symptoms
    Sedation, dribbling, drooling, weight gain and diabetes
Thienobenzodiazepines Olanzapine Sedation, weight gain and diabetes
    Low incidence of extrapyramidal side effects and low impact on prolactin
  Quetiapine Low incidence of extrapyramidal side effects and low impact on prolactin
  Zotepine Similar to olanzapine but higher rate of prolactin elevation and higher rate of drug-induced seizures
Serotonin–dopamine antagonists Risperidone Extrapyramidal side effects at higher doses. High rate of prolactin elevation
  Paliperidone As risperidone
  Ziprasidone As risperidone
  Sertindole Available on named patient basis only due to risk of sudden cardiac events
Partial dopamine agonist Aripiprazole Low level of side effects but light-headedness and blurred vision common

A significant factor that has influenced prescribing practice in schizophrenia in recent years has been an improved understanding of the role of clozapine in treatment-resistant schizophrenia.

Clozapine and refractory illness

Clozapine was developed as an antipsychotic drug during the 1960s. Unfortunately, use is associated with a 1–2% incidence of neutropenia and this initially resulted in the withdrawal of the drug from clinical practice. However, it was noted even at an early stage in the drug’s history that it was free of the extrapyramidal side frequently seen with the other antipsychotic drugs. In the 1980s, clozapine was demonstrated to have a greater efficacy than other antipsychotics (Kane et al., 1988; Lieberman et al., 1994) and was subsequently reintroduced into clinical practice but with routine monitoring of blood mandatory.

Clozapine is now established as the drug of choice in treatment-resistant schizophrenia but it is not without problems (Tuunainen et al., 2000). In addition to neutropenia, it is associated with a greater risk of seizures, particularly if doses are above 600 mg daily. Some guidelines recommend the co-prescribing of sodium valproate to reduce this risk. In addition, use is associated with excessive drooling, hypotension and sedation during the early stages of treatment, requiring slow dose increases initially.

A regimen of gradual dose increases starting at 12.5 mg twice daily aiming to reach 300 mg in 2–3 weeks is normally recommended. However, this rate of dose increase is frequently too rapid, with tachycardia being a particular problem. In such cases, it is usual to slow down the rate of dose increase to a half or a quarter of that recommended. Although tachycardia is a common problem with clozapine initiation, if use is associated with fever, chest pain or hypotension this may indicate a high risk of myocarditis and the drug should be stopped (Committee on Safety of Medicines, 2002).

Augmentation strategies and polytherapy

Schizophrenia is a complex illness with a very varied presentation. In addition to the core symptoms, elements of other mental illnesses such as mania, depression and anxiety may predominate. Controversy remains about whether these associated symptoms should be treated separately or as a part of schizophrenia. In addition, there is debate about whether these presentations represent an alternative diagnosis, for example, schizoaffective disorder when the mood disorder is a primary component of the presentation. The current fashion is for these components of the illness to be treated separately, with much resulting polytherapy with SSRI antidepressants and antiepileptic drugs for mood control.

In addition to the above, complex prescriptions can arise when treatment with clozapine is perceived to be inadequate or doses are limited due to side effects. The theory behind the addition of a further drug can be either that the plasma concentration of the clozapine will be enhanced by the addition of another drug, or the second drug will enhance a particular receptor blockade which may be considered necessary in a specific patient (Cipriani et al., 2009; Paton et al., 2007). The augmentation strategy with the best evidence to support its use is the addition of sulpiride or amisulpride to clozapine. Other strategies include the addition of risperidone, lamotrigine or Ω3 fatty acids. However, many of the trials that support these augmentation strategies are small scale and a meta-analysis concluded that no single strategy was superior to another (Paton et al., 2007).

Long-acting formulations of antipsychotic drugs

Most long-acting (depot) formulations, including the long-acting olanzapine formulation, are synthesised by esterification of the hydroxyl group of the antipsychotic drug to a long chain fatty acid such as decanoic acid. The esters which are more lipophilic and soluble are dissolved in an oily vehicle such as sesame oil or a vegetable oil (viscoleo). Once the drug is injected into muscle it is slowly released from the oil vehicle. Active drug becomes available following hydrolysis for distribution to the site of the action. A long-acting injection of olanzapine has been marketed which contains a salt of olanzapine and pamoic acid suspended in an aqueous vehicle. This also is designed for intramuscular injection every 2–4 weeks.

Although the ideal long-acting antipsychotic formulation should release the drug at a constant rate so that plasma level fluctuations are kept to a minimum, all the available products produce significant variations (Table 30.3). This can result in increased side effects at the time of peak plasma concentrations, usually after 5–7 days, for oil-based depots and increased patient irritability towards the end of the period, as plasma concentrations decline. For many patients though, oil-based long-acting formulations result in a very slow decline in drug availability after a period of chronic administration (Altamura et al., 2003). When transferring a patient from depot formulations to oral administration, it may be many months before the effect of the depot finally wears off.

Long-acting risperidone injection involves a microsphere formulation. The microspheres delay the release of risperidone for 3–4 weeks. Once release has commenced, the risperidone reaches a maximum concentration 4–5 weeks after the injection with a decline over the subsequent 2–3 weeks. This more rapid decline has an advantage that by 2 months after the last injection, little of the risperidone will remain. The delay in onset is often a reason for relapse as it is necessary to maintain oral supplementation for at least 6 weeks and this may be overlooked.

In addition to the principles of drug choice and dosage selection that apply to oral drugs, with depot therapy there is also a need to consider the future habitation of the patient. If the patient is to live an independent lifestyle, depot formulations are indicated, but if the person is to remain in staffed accommodation and receive other medicines routinely administered by a nurse, the use of depot formulations may not be logical.

Adverse effects and antipsychotic medicines

There are a large number of adverse effects associated with antipsychotic medicines. Some of these effects, such as sedation, antilibido effects and weight gain may be considered to be of value with particular patients, but the susceptibility to such adverse effects is often a major factor in determining drug choice. Prescribing guidelines are available (Bazire, 2009; Taylor et al., 2009) which provide details of the relative likelihood of side effects with the various antipsychotic drugs. The major side effects are set out below.

Neuroleptic malignant syndrome (NMS)

The NMS is a rare but serious complication of antipsychotic drug treatment. The primary symptoms are rigidity, fever, diaphoresis, confusion and fluctuating consciousness. Confirmation can be sought through detection of elevated levels of creatinine kinase. The onset is particularly associated with high-potency typical drugs such as haloperidol, recent and rapid changes to dose and abrupt withdrawal of anticholinergic drugs. Treatment usually requires admission to a medical ward and withdrawal of all antipsychotic drugs.

Case studies

Answers

Answers

Ideally all other treatments would be stopped and clozapine prescribed alone. Sometimes the final step of withdrawing other medicines may occur during the initiation phase with clozapine.

References

Altamura A., Sassella F., Santini A., et al. Intramuscular preparations of antipsychotics uses and relevance in clinical practice. Drugs. 2003;63:493-512.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, fourth ed. Washington: American Psychiatric Association; 1994.

Bazire S. Psychotropic Drug Directory: The Professionals’ Pocket Handbook and Aide Memoire. Salisbury: Fivepin Ltd; 2009.

Chakos M., Lieberman J.A., Hoffman E., et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry. 2001;158:518-526.

Cipriani A., Boso M., Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst. Rev.. (3):2009. Art. No. CD006324 doi: 10.1002/14651858.CD006324.pub2. Available at: http://www2.cochrane.org/reviews/en/ab006324.html

Committee on Safety of Medicines. Clozapine and cardiac safety: updated advice for prescribers. Curr. Probl. Pharmacovigil.. 2002;28:8.

Kane J., Honigfield G., Singer J., et al. Clozapine for the treatment-resistant schizophrenic; a double blind comparison with chlorpromazine (clozaril collaborative study). Arch. Gen. Psychiatry. 1988;45:789-796.

Lieberman J.A., Safferman A.Z., Pollack S., et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am. J. Psychiatry. 1994;15:1744-1752.

National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care. Clinical guideline 82 update http://www.nice.org.uk/nicemedia/live/11786/43608/43608.pdf, 2009.

Paton C., Whittington C., Barnes T. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J. Clin. Psychopharmacol.. 2007;27:198-204.

Royal College of Psychiatrists. Consensus Statement on High-Dose Antipsychotic Medication. London: RCP; 2006. CR138

Taylor D., Paton C., Kapur S. The Maudsley Prescribing Guidelines, 10th ed. London: Informa Healthcare; 2009.

Tuunainen A., Wahlbeck K., Gilbody S. Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database Syst. Rev.. (1):2000. Art No. CD000966. doi: 10.1002/14651858.CD000966

World Health Organization. International Classification of Diseases and Related Health Problems, 10th ed. Geneva: World Health Organization; 1992. (ICD 10)